Organogenesis Holdings Inc. (NASDAQ:ORGO)’s traded shares stood at 2.1 million during the last session, with the company’s beta value hitting 1.38. At the close of trading, the stock’s price was $2.16. The ORGO share’s 52-week high remains $8.27, putting it -282.87% down since that peak but still an impressive 1.85% since price per share fell to its 52-week low of $2.12. The company has a valuation of $287.04M, with an average of 2.03 million shares in intraday trading volume over the past 10 days and average of 920.62K shares over the past 3 months.

Analysts have given a consensus recommendation of a Hold for Organogenesis Holdings Inc. (ORGO), translating to a mean rating of 3.00. Of 1 analyst(s) looking at the stock, 0 analyst(s) give ORGO a Sell rating. 0 of those analysts rate the stock as Overweight while 1 advise Hold as 0 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at $0.05.

Organogenesis Holdings Inc. (NASDAQ:ORGO) trade information

Organogenesis Holdings Inc. (ORGO) has traded red over the past five days. The stock hit a weekly high of 2.36 this Wednesday, 03/15/23. The 5-day price performance for the stock is -7.69%, and -22.02% over 30 days. With these gigs, the year-to-date price performance is -19.70%. Short interest in Organogenesis Holdings Inc. (NASDAQ:ORGO) saw shorts transact 5.75 million shares and set a 7.43 days time to cover.

Analysts on Wall Street suggest a consensus price target of $11.00, implying an increase of 80.36% to the stock’s current value. The extremes give us $11.00 and $11.00 for target low and target high price respectively. As such, ORGO has been trading -409.26% off suggested target high and -409.26% from its likely low.

Organogenesis Holdings Inc. (ORGO) estimates and forecasts

The rating firms project that company’s revenue will shrink -2.00% compared to the previous financial year.

Revenue forecast for the current quarter as set by 1 analysts is $122.4 million. Meanwhile, for the quarter ending Mar 2023, a total of 1 analyst(s) estimate revenue growth to $108.9 million.Earnings reports from the last fiscal year show that sales brought in $128.56 million and $98.12 million respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to fall -4.80% before jumping 11.00% in the following quarter.

An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 17.60% for the past 5-year period. While 2023 is set for a -83.50% return in earnings, projections for the next 5 years are at 2.41% annually.

ORGO Dividends

Organogenesis Holdings Inc. has its next earnings report out between May 08 and May 12. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Organogenesis Holdings Inc. has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.

Organogenesis Holdings Inc. (NASDAQ:ORGO)’s Major holders

Organogenesis Holdings Inc. insiders hold 50.57% of total outstanding shares, with institutional holders owning 43.10% of the shares at 87.19% float percentage. In total, 43.10% institutions holds shares in the company, led by Blackrock Inc. As of Sep 29, 2022, the company held over 10.54 million shares (or 8.05% of shares), all amounting to roughly $34.14 million.

The next major institution holding the largest number of shares is Soleus Capital Management, L.P. with 6.49 million shares, or about 4.96% of shares outstanding. As of the market price on Sep 29, 2022, these shares were worth $21.02 million.

We also have iShares Core S&P Smallcap ETF and Vanguard Total Stock Market Index Fund as the top two Mutual Funds with the largest holdings of the Organogenesis Holdings Inc. (ORGO) shares. Going by data provided on Dec 30, 2022, iShares Core S&P Smallcap ETF holds roughly 5.31 million shares. This is just over 4.06% of the total shares, with a market valuation of $14.28 million. Data from the same date shows that the other fund manager holds a little less at 1.88 million, or 1.44% of the shares, all valued at about 6.1 million.